ACMG recognizes progress made in newborn screening

In support of the latest March of Dimes Newborn Screening Report Card, the American College of Medical Genetics (ACMG) strongly urges every state to require complete testing of all newborns for a 'core panel' of genetic and congenital conditions.

It is estimated that currently more than 500,000 babies annually are still not screened for the full panel of debilitating or life-threatening disorders. In many of these diseases, serious complications such as death or mental retardation are avoidable only through newborn screening, with appropriate follow-up and treatment.

The Executive Summary of Newborn Screening: Toward a Uniform Screening Panel and System is available to download at: http://www.acmg.net/resources/policies/NBS/NBS-sections.htm and the Newborn Screening ACT sheets are available at http://www.acmg.net/resources/policies/ACT/condition-analyte-links.htm. The March of Dimes also offers information about the recommended newborn screening tests at www.marchofdimes.com/nbs.

"More thorough newborn screening programs will save lives and reduce disabilities. Advances in technology have made it possible and feasible to test newborns for a number of serious or deadly diseases, which can then be treated. With the current expansion of newborn screening panels, it is estimated that about 10,000 of the 4.1 million babies born each year in the United States will be identified with one of the conditions for which treatment will have a significant impact on long-term outcome. At ACMG, we will continue to monitor new advancements in testing and screening and translating these genetic discoveries into recommendations to improve public health and save lives, " said Michael S. Watson, PhD, ACMG executive director.

"When newborn screening detects an abnormality, early diagnosis and treatment can make the difference between a healthy life and one that is shortened or requires long-term care. These tests can make a huge difference to a child and family," said Joe Leigh Simpson, MD, FACMG, FACOG, President of the American College of Medical Genetics.

The ACMG Newborn Screening report released in May 2006 was commissioned by the Maternal and Child Health Bureau of the U.S. Health Resources and Services Administration and written by the ACMG Newborn Screening Expert Group, which included representatives of the Centers for Disease Control and Prevention, the Health Resources and Services Administration, the National Institutes of Health, the American Academy of Pediatrics, the March of Dimes Birth Defects Foundation, and the Genetic Alliance as well as experts in health policy, law, ethics, public health and consumer advocacy group representatives.

All of the conditions recommended for inclusion in the core screening panel can be identified shortly after birth, but would not ordinarily be detected without testing. For each of the core diseases, an accurate test is currently available and there are demonstrated benefits of early detection and treatment. Further, ACMG has recently made available to all pediatricians and newborn screening programs in the United States a set of materials (ACT(ion) sheets and algorithms for diagnostic confirmation to guide them through the process of confirming the diagnosis in a baby who has a positive screening test result.

"We need expanded newborn screening in the United States. Newborn screening costs so little and yet can save so much," said R. Rodney Howell, MD, FACMG, president of the American College of Medical Genetics Foundation.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
New genetic model offers insights into breast cancer metastasis